CorMedix Inc (NASDAQ:CRMD – Get Free Report) CEO Joseph Todisco acquired 80,000 shares of CorMedix stock in a transaction that occurred on Friday, November 13th. The shares were purchased at an average cost of $4.89 per share, with a total value of $391,200.00. Following the transaction, the chief executive officer owned 854,749 shares of the company’s stock, valued at approximately $4,179,722.61. The trade was a 10.33% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
CorMedix Stock Down 3.6%
Shares of CRMD stock opened at $4.50 on Thursday. CorMedix Inc has a twelve month low of $4.49 and a twelve month high of $13.02. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.43. The stock’s 50 day simple moving average is $6.96 and its 200 day simple moving average is $7.52. The company has a market capitalization of $357.93 million, a price-to-earnings ratio of 3.62, a PEG ratio of 1.07 and a beta of 1.48.
CorMedix (NASDAQ:CRMD – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 26.70%. The company had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. As a group, research analysts predict that CorMedix Inc will post 0.44 EPS for the current year.
Institutional Trading of CorMedix
Analyst Upgrades and Downgrades
CRMD has been the subject of several research analyst reports. Royal Bank Of Canada boosted their price target on shares of CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday, November 10th. Oppenheimer reiterated an “outperform” rating and set a $13.00 target price (down from $15.00) on shares of CorMedix in a report on Friday, November 13th. Needham & Company LLC lifted their price objective on shares of CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Weiss Ratings cut CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, November 10th. Finally, Citigroup reissued a “market outperform” rating on shares of CorMedix in a report on Tuesday, November 10th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, CorMedix currently has an average rating of “Moderate Buy” and an average price target of $15.22.
Read Our Latest Stock Analysis on CorMedix
CorMedix Company Profile
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Featured Stories
- Five stocks we like better than CorMedix
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
